Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home Use

NCT ID: NCT06124638

Last Updated: 2024-08-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 624 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-04
• Study Completion Date: 2024-04-03

Brief Summary

This study is designed to demonstrate the performance and usability of the the Panbio™ COVID-19/Flu A&B Panel Self Test in the hands of patients/lay-users. Nasal swabs will be self-collected by subjects/lay-users who are symptomatic and suspected of viral respiratory infection. They will perform, read, and interpret the test result. The test is intended for nonprescription home use for qualitative detection of COVID-19, Influenza A antigen, and Influenza B antigen.

Detailed Description

The total number of anterior nasal swabs collected from each consented Participant is two (2). Participants at least two (2) years of age meeting eligibility criteria will be enrolled.

The order of nasal swab collection will be randomized according to the Participant ID as to which swab is used for Panbio™ COVID-19/Flu A&B Panel Self Test and which is to be eluted into VTM for comparator testing. Site staff should allow for a minimum 15 minute period between the 2 swabs to allow for normalization of the swabbing site. For Participants with an odd numbered Participant ID, the first swab collected will be used for Panbio™ COVID-19/Flu A&B Panel Self Test and the second swab collected will be eluted into VTM for comparator testing. For Participants with an even numbered Participant ID, the first swab collected will be eluted into VTM for comparator testing and the second swab collected will be used for Panbio™ COVID-19/Flu A&B Panel Self Test.

Sample collection for the Self Test:

Each Participant (lay user who will be a self-tester or caregiver) from whom informed consent has been obtained will be provided a single use test kit containing a Panbio™ COVID-19/Flu A&B Panel Self Test and a sterile nasal swab. The Participant will self-collect one (1) anterior nasal swab, perform the Panbio™ COVID- 19/Flu A&B Panel Self Test, then interpret and record the result. Parents of pediatric participants under the age of 14 or Legally Authorized Representatives of adult Participants unable to perform self-collection will collect one (1) anterior nasal swab from the Participant, perform the Panbio™ COVID-19/Flu A&B Panel Self Test, then interpret and record the result. To simulate a home environment testing will occur in a designated room/area that does not contain medical equipment. The designated room/area will at minimum contain a table/counter, chair and lamp for testing. The participant will be provided with the Instructions for Use prior to testing. Participants will not be able to observe other participants conducting testing. The Participant will follow Panbio instructions to insert the swab up to one inch first into the right nostril, to rotate/swirl the swab five (5) times to obtain sample, then remove and insert the same swab into the left nostril, repeating the rotate/swirl technique. After sample collection, Participants will test the sample on the Panbio™ COVID-19/Flu A&B Panel Self Test and interpret the results. Participants will be asked to document their result interpretation, and will pass the completed test to site staff, who will independently and separately document their interpretation of the result. Site staff will interpret the test immediately and at the same time photograph the test result. Site staff will be blinded to the test result recorded by the Participant. Participants/lay users, caregivers, and site staff will be blinded to a Participant's standard of care COVID-19 and/or Flu test results.

Sample collection for the comparator:

Site staff will collect one (1) anterior nasal swab from the Participant by inserting the swab 1-2 cm into one of the anterior nares. Staff will rotate the swab against the nasal mucosa for about 3 seconds and withdraw. Staff will repeat with the other anterior nare using the same swab, and vigorously elute the swab in Viral Transport Medium (VTM). VTM will be send to the central lab and be tested with reverse transcriptase - Polymerase Chain Reaction (RT-PCR).

Conditions

COVID-19; Influenza A; Influenza Type B

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Self-Testing Group

Lay users (self-tester or caregiver) will be provided with a Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test kit. Each lay user will collect one mid-turbinate nasal swab from both nostrils, perform and interpret the Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test. All procedures for testing and result interpretation, including sample collection and extraction will be conducted by the lay user following the Instructions for Use provided in the kit. Participants will be asked to document their result interpretation and will pass the test to site staff, who will document their interpretation of the result. In addition, a second swab will be collected by study staff and eluted in Viral Transport Medium (VTM).

Group Type: EXPERIMENTAL

Panbio™ COVID-19/Flu A&B Panel

Intervention Type: DIAGNOSTIC_TEST

The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users.

Interventions

Panbio™ COVID-19/Flu A&B Panel

The Panbio™ COVID-19/Flu A\&B Rapid Panel Self-Test device is a visual lateral flow assay, for rapid immunochromatographic qualitative detection of COVID-19 antigen, Influenza A antigen and Influenza B antigen in self-collected mid-turbinate nasal swabs. The test is designed to be used by lay users.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Participant is at least two (2) years of age, and
• Participant is suspected of acute viral respiratory infection by a healthcare professional, and
• Participant is within seven (7) days of symptom onset, and
• Participant is experiencing two or more of the following symptoms

• Fever of >100.0°F/ 37.8°C
• Cough
• Fatigue
• New loss of taste or smell
• Congestion or runny nose
• Shortness of breath or difficulty breathing
• Sore throat
• Muscle or body aches
• Headache
• Nausea or vomiting
• Diarrhea

Exclusion Criteria

• Participant is currently enrolled in a study to evaluate an investigational drug or experimental treatment
• Participants with an active nosebleed
• Participant has undergone a nasal wash or nasal aspirate procedure on day of enrolment
• Participant has received a nasal spray or mist Influenza vaccine (i.e. FluMist) within the last 30 days
• Participant has tested positive for COVID-19 within the last 45 days (excluding test results received after current onset of symptoms)
• Participant has received antiviral medications for Influenza (Amantadine, Rimantadine, Ribavirin, Oseltamivir, Zanamivir) in the previous 45 days
• Participant has received medication or treatment for COVID-19 infection in the last 45 days (including antivirals, convalescent plasma therapy, monoclonal antibody treatment (mAb), Remdesivir, long-acting antibody (LAAB) treatment (Evusheld)

• Minimum Eligible Age: 2 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott Rapid Dx

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Cahaba Research Inc

Pelham, Alabama, United States

Maimonides Medical Center

Brooklyn, New York, United States

Countries

United States

Other Identifiers

2324101

Identifier Type: -

Identifier Source: org_study_id